Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Increased Circulating Pentraxin 3 Levels in Patients with Rheumatoid Arthritis: A Meta-analysis

Author(s): Shi-Yang Guan, Yuting Chen, Ming Shao, Hui Yang, Wei Xu, Zongwen Shuai, Hui Zhao, Dahai Zhao* and Faming Pan*

Volume 28, Issue 27, 2022

Published on: 12 August, 2022

Page: [2260 - 2269] Pages: 10

DOI: 10.2174/1381612828666220614155037

Price: $65

Abstract

Background: Pentraxin 3 (PTX3), a soluble pattern recognition molecule, not only acts as a promising indicator reflecting the disease activity of rheumatoid arthritis (RA) patients but exerts essential pathogenic roles in the progression of RA and serves as a potential therapeutic target for RA patients. Our study intends to systematically evaluate the circulating PTX3 levels and their potential influencing factors in RA patients.

Methods: Articles regarding the circulating PTX3 levels of RA patients were identified in Pubmed, Embase, China National Knowledge Infrastructure (CNKI), and Cochrane databases. Standardized mean difference (SMD) and corresponding 95% confidence intervals (95% CI) were calculated and further illustrated by the forest plot. Egger’s regression test and sensitivity analysis were conducted to assess the publication bias and stability of the results, respectively.

Results: Twenty articles with 21 individual studies were recruited in our meta-analysis. The overall results revealed that compared to healthy controls, RA patients had significantly higher circulating PTX3 levels (pooled SMD = 0.97, 95% CI: 0.48 to 1.45). Subgroup analyses further demonstrated that compared to healthy controls, RA patients of age ≤ 50 years, 2.6 < disease activity score in 28 joints (DAS28) ≤ 3.2, 3.2 < DAS28 ≤ 5.1, DAS28 > 5.1, C-reactive protein (CRP) levels > 10 mg/L, erythrocyte sedimentation rate (ESR) > 20 mm/h, and disease duration > 5 years had significantly higher circulating PTX3 levels, respectively; whereas RA patients of age > 50 years, DAS28 ≤ 2.6, CRP levels ≤ 10 mg/L, ESR ≤ 20 mm/h and disease duration ≤ 5 years had no significantly altered circulating PTX3 levels, respectively. Additionally, no matter whether the patients were of Caucasian ethnicity or not, circulating PTX3 levels were significantly increased in RA patients.

Conclusion: Compared to healthy controls, circulating PTX3 levels are significantly increased in RA patients, which are influenced by age, disease activity, CRP levels, ESR, and disease duration.

Keywords: Autoimmune diseases, C-reactive protein, disease activity, inflammation, pentraxin 3, rheumatoid arthritis, soluble pattern recognition molecule.

« Previous Next »
[1]
Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers 2018; 4: 18001.
[http://dx.doi.org/10.1038/nrdp.2018.1] [PMID: 29417936]
[2]
Scherer HU, Häupl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun 2020; 110: 102400.
[http://dx.doi.org/10.1016/j.jaut.2019.102400] [PMID: 31980337]
[3]
Sparks JA. Rheumatoid arthritis. Ann Intern Med 2019; 170(1): ITC1-ITC16.
[http://dx.doi.org/10.7326/AITC201901010] [PMID: 30596879]
[4]
Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: Results from olmsted county, minnesota, 1955-2007. Arthritis Rheum 2010; 62(6): 1576-82.
[http://dx.doi.org/10.1002/art.27425] [PMID: 20191579]
[5]
Guan SY, Leng RX, Tao JH, et al. Hypoxia-inducible factor-1α: A promising therapeutic target for autoimmune diseases. Expert Opin Ther Targets 2017; 21(7): 715-23.
[http://dx.doi.org/10.1080/14728222.2017.1336539] [PMID: 28553732]
[6]
McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017; 389(10086): 2328-37.
[http://dx.doi.org/10.1016/S0140-6736(17)31472-1] [PMID: 28612747]
[7]
Inforzato A, Bottazzi B, Garlanda C, Valentino S, Mantovani A. Pentraxins in humoral innate immunity. Adv Exp Med Biol 2012; 946: 1-20.
[http://dx.doi.org/10.1007/978-1-4614-0106-3_1] [PMID: 21948359]
[8]
Ortega-Hernandez OD, Bassi N, Shoenfeld Y, Anaya JM. The long pentraxin 3 and its role in autoimmunity. Semin Arthritis Rheum 2009; 39(1): 38-54.
[http://dx.doi.org/10.1016/j.semarthrit.2008.03.006] [PMID: 18614204]
[9]
Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: Pentraxins as a paradigm. Annu Rev Immunol 2010; 28: 157-83.
[http://dx.doi.org/10.1146/annurev-immunol-030409-101305] [PMID: 19968561]
[10]
Wu Q, Cao F, Tao J, Li X, Zheng SG, Pan HF. Pentraxin 3: A promising therapeutic target for autoimmune diseases. Autoimmun Rev 2020; 19(12): 102584.
[http://dx.doi.org/10.1016/j.autrev.2020.102584] [PMID: 32534154]
[11]
Luchetti MM, Piccinini G, Mantovani A, et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol 2000; 119(1): 196-202.
[http://dx.doi.org/10.1046/j.1365-2249.2000.01110.x] [PMID: 10606983]
[12]
Inforzato A, Doni A, Barajon I, et al. PTX3 as a paradigm for the interaction of pentraxins with the complement system. Semin Immunol 2013; 25(1): 79-85.
[http://dx.doi.org/10.1016/j.smim.2013.05.002] [PMID: 23747040]
[13]
Zhao S, Wang Y, Hou L, Wang Y, Xu N, Zhang N. Pentraxin 3 inhibits fibroblast growth factor 2 induced osteoclastogenesis in rheumatoid arthritis. Biomed Pharmacother 2020; 131: 110628.
[http://dx.doi.org/10.1016/j.biopha.2020.110628] [PMID: 32890968]
[14]
García S, Forteza J, López-Otin C, Gómez-Reino JJ, González A, Conde C. Matrix metalloproteinase-8 deficiency increases joint inflammation and bone erosion in the K/BxN serum-transfer arthritis model. Arthritis Res Ther 2010; 12(6): R224.
[http://dx.doi.org/10.1186/ar3211] [PMID: 21190566]
[15]
Kiszewska N, Bień E, Irga-Jaworska N, Adamkiewicz-Drożyńska E. Selected inflammatory markers in the diagnosis and monitoring of infections in children treated for hematological malignancies. Biomarkers Med 2015; 9(5): 461-71.
[http://dx.doi.org/10.2217/bmm.14.101] [PMID: 25985175]
[16]
Doni A, Garlanda C, Bottazzi B, Meri S, Garred P, Mantovani A. Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology 2012; 217(11): 1122-8.
[http://dx.doi.org/10.1016/j.imbio.2012.07.004] [PMID: 22964239]
[17]
Garlanda C, Jaillon S, Doni A, Bottazzi B, Mantovani A. PTX3, a humoral pattern recognition molecule at the interface between microbe and matrix recognition. Curr Opin Immunol 2016; 38: 39-44.
[http://dx.doi.org/10.1016/j.coi.2015.11.002] [PMID: 26650391]
[18]
Kasperska-Zajac A, Grzanka A, Misiolek M, Mazur B, Machura E. Pentraxin-3 as a local inflammatory marker in chronic spontaneous urticaria. Cytokine 2015; 76(2): 566-8.
[http://dx.doi.org/10.1016/j.cyto.2015.04.016] [PMID: 25982553]
[19]
Wen X, Hou R, Xu K, et al. Pentraxin 3 is more accurate than c-reactive protein for takayasu arteritis activity assessment: A systematic review and meta-analysis. PLoS One 2021; 16(2): e0245612.
[http://dx.doi.org/10.1371/journal.pone.0245612] [PMID: 33529185]
[20]
Inoue K, Kodama T, Daida H. Pentraxin 3: A novel biomarker for inflammatory cardiovascular disease. Int J Vasc Med 2012; 2012: 657025.
[http://dx.doi.org/10.1155/2012/657025] [PMID: 22347626]
[21]
Qiu C, Han Y, Zhang H, et al. Perspectives on long pentraxin 3 and rheumatoid arthritis: Several potential breakthrough points relying on study foundation of the past. Int J Med Sci 2021; 18(8): 1886-98.
[http://dx.doi.org/10.7150/ijms.54787] [PMID: 33746606]
[22]
Balbaloglu O, Ozcan SS. Is pentraxin 3 level an effective biomarker in disease activity in patients with rheumatoid arthritis? Arch Med Sci 2019; 16(1): 81-6.
[http://dx.doi.org/10.5114/aoms.2017.69726] [PMID: 32051709]
[23]
Asanuma YF, Aizaki Y, Noma H, et al. Plasma pentraxin 3 is associated with progression of radiographic joint damage, but not carotid atherosclerosis, in female rheumatoid arthritis patients: 3-year prospective study. Mod Rheumatol 2020; 30(6): 959-66.
[PMID: 31615315]
[24]
Södergren A, Karp K, Bengtsson C, Möller B, Rantapää-Dahlqvist S, Wållberg-Jonsson S. Biomarkers associated with cardiovascular disease in patients with early rheumatoid arthritis. PLoS One 2019; 14(8): e0220531.
[http://dx.doi.org/10.1371/journal.pone.0220531] [PMID: 31381601]
[25]
Sağ MS, Sağ S, Tekeoğlu İ, Kamanli A, Nas K, Harman H. The relationship between serum pentraxine 3 levels and hematological markers in patients with rheumatoid arthritis. Arch Rheumatol 2017; 33(1): 39-44.
[http://dx.doi.org/10.5606/ArchRheumatol.2018.6394] [PMID: 29900992]
[26]
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: The prisma statement. BMJ 2009; 339: b2535.
[http://dx.doi.org/10.1136/bmj.b2535] [PMID: 19622551]
[27]
Stang A. Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25(9): 603-5.
[http://dx.doi.org/10.1007/s10654-010-9491-z] [PMID: 20652370]
[28]
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135.
[http://dx.doi.org/10.1186/1471-2288-14-135] [PMID: 25524443]
[29]
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.
[http://dx.doi.org/10.1186/1471-2288-5-13] [PMID: 15840177]
[30]
Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23(5)(Suppl. 39): S93-9.
[PMID: 16273792]
[31]
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-58.
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[32]
Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 2010; 1(2): 97-111.
[http://dx.doi.org/10.1002/jrsm.12] [PMID: 26061376]
[33]
Ramirez GA, Rovere-Querini P, Blasi M, et al. PTX3 intercepts vascular inflammation in systemic immune-mediated diseases. Front Immunol 2019; 10: 1135.
[http://dx.doi.org/10.3389/fimmu.2019.01135] [PMID: 31191526]
[34]
Wang Z. The correlation of PTX-3, IL-6 and CRP with disease activity in RA. Curr Immunol 2019; 39: 490-4.
[35]
Chen X, Chen B, Li T, Shi S, Zhu Y. Expression and clinical significance of serum pentraxin-3 in patients with rheumatoid arthritis. Xiandai Yixue 2019; 47: 1305-9.
[36]
Jafari-Nakhjavani M, Ghorbanihaghjo A, Pourghassem E, Abediazar S, Pourlak T, Malekmahdavi A. Serum pentraxin 3 levels in rheumatoid arthritis patients and its association with disease activity. Egypt Rheumatol 2019; 41: 251-4.
[http://dx.doi.org/10.1016/j.ejr.2018.11.006]
[37]
Tekeoğlu İ, Harman H, Sağ S, Altındiş M, Kamanlı A, Nas K. Levels of serum pentraxin 3, IL-6, fetuin A and insulin in patients with rheumatoid arthritis. Cytokine 2016; 83: 171-5.
[http://dx.doi.org/10.1016/j.cyto.2016.04.009] [PMID: 27152709]
[38]
Kahlow BS, Petisco R, Skare TL, Goeldner I, Nisihara RM, Messias-Reason IJ. Serum pentraxin 3 levels are negatively associated with carotid intima media thickness in non-obese rheumatoid arthritis patients. Int J Cardiol 2016; 221: 298-301.
[http://dx.doi.org/10.1016/j.ijcard.2016.06.175] [PMID: 27404695]
[39]
Klimek E, Skalska A, Kwaśny-Krochin B, et al. Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration. Mediators Inflamm 2014; 2014: 681635.
[http://dx.doi.org/10.1155/2014/681635] [PMID: 24864133]
[40]
Liou LB, Tsai WP, Chang CJ, Chao WJ, Chen MH. Blood monocyte chemotactic protein-1 (MCP-1) and adapted disease activity Score28-MCP-1: Favorable indicators for rheumatoid arthritis activity. PLoS One 2013; 8(1): e55346.
[http://dx.doi.org/10.1371/journal.pone.0055346] [PMID: 23383162]
[41]
Hollan I, Nebuloni M, Bottazzi B, et al. Pentraxin 3, a novel cardiovascular biomarker, is expressed in aortic specimens of patients with coronary artery disease with and without rheumatoid arthritis. Cardiovasc Pathol 2013; 22(5): 324-31.
[http://dx.doi.org/10.1016/j.carpath.2013.01.007] [PMID: 23434196]
[42]
Sun Y, Ma LL, Liu H, et al. The value of pentraxin-3 (PTX-3) for evaluating disease status in Takayasu's arteritis (TA) Fudan Univ J Med Sci 2013; 40: 390-394, 406.
[43]
Baldini M, Maugeri N, Ramirez GA, et al. Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia. Arthritis Rheum 2012; 64(3): 854-65.
[http://dx.doi.org/10.1002/art.33411] [PMID: 21989653]
[44]
Mabrouk MM, Ghazy MA, Hassan TM. Serum pentraxin 3 and interleukin-6 are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis. Egypt J Immunol 2010; 17(1): 87-99.
[PMID: 22053612]
[45]
Hollan I, Bottazzi B, Cuccovillo I, et al. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. Arthritis Care Res (Hoboken) 2010; 62(3): 378-85.
[http://dx.doi.org/10.1002/acr.20094] [PMID: 20391484]
[46]
Rovere-Querini P, Antonacci S, Dell’Antonio G, et al. Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia. Obstet Gynecol 2006; 108(1): 148-55.
[http://dx.doi.org/10.1097/01.AOG.0000224607.46622.bc] [PMID: 16816069]
[47]
Fazzini F, Peri G, Doni A, et al. PTX3 in small-vessel vasculitides: An independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001; 44(12): 2841-50.
[http://dx.doi.org/10.1002/1529-0131(200112)44:12<2841:AID-ART472>3.0.CO;2-6] [PMID: 11762945]
[48]
Boutet MA, Nerviani A, Lliso-Ribera G, et al. Circulating and synovial pentraxin-3 (PTX3) expression levels correlate with rheumatoid arthritis severity and tissue infiltration independently of conventional treatments response. Front Immunol 2021; 12: 686795.
[http://dx.doi.org/10.3389/fimmu.2021.686795] [PMID: 34248970]
[49]
Bottazzi B, Inforzato A, Messa M, et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol 2016; 64(6): 1416-27.
[http://dx.doi.org/10.1016/j.jhep.2016.02.029] [PMID: 26921689]
[50]
Inforzato A, Jaillon S, Moalli F, et al. The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodelling. Tissue Antigens 2011; 77(4): 271-82.
[http://dx.doi.org/10.1111/j.1399-0039.2011.01645.x] [PMID: 21388349]
[51]
Cotena A, Maina V, Sironi M, et al. Complement dependent amplification of the innate response to a cognate microbial ligand by the long pentraxin PTX3. J Immunol 2007; 179(9): 6311-7.
[http://dx.doi.org/10.4049/jimmunol.179.9.6311] [PMID: 17947708]
[52]
van Rossum AP, Fazzini F, Limburg PC, et al. The prototypic tissue pentraxin PTX3, in contrast to the short pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages. Arthritis Rheum 2004; 50(8): 2667-74.
[http://dx.doi.org/10.1002/art.20370] [PMID: 15334483]
[53]
Mahnke K, Johnson TS, Ring S, Enk AH. Tolerogenic dendritic cells and regulatory T cells: A two-way relationship. J Dermatol Sci 2007; 46(3): 159-67.
[http://dx.doi.org/10.1016/j.jdermsci.2007.03.002] [PMID: 17428639]
[54]
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: A review. JAMA 2018; 320(13): 1360-72.
[http://dx.doi.org/10.1001/jama.2018.13103] [PMID: 30285183]
[55]
Wu XY, Li KT, Yang HX, et al. Complement C1q synergizes with PTX3 in promoting NLRP3 inflammasome over-activation and pyroptosis in rheumatoid arthritis. J Autoimmun 2020; 106: 102336.
[http://dx.doi.org/10.1016/j.jaut.2019.102336] [PMID: 31601476]
[56]
Yokota K, Miyoshi F, Sato K, Asanuma Y, Akiyama Y, Mimura T. Geranylgeranyl-pyrophosphate regulates secretion of pentraxin 3 and monocyte chemoattractant protein-1 from rheumatoid fibroblast-like synoviocytes in distinct manners. Clin Exp Rheumatol 2011; 29(1): 43-9.
[PMID: 21345291]
[57]
Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: A critical review. J Intern Med 2008; 264(4): 295-314.
[http://dx.doi.org/10.1111/j.1365-2796.2008.02015.x] [PMID: 18823504]
[58]
Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med 2009; 47(4): 471-7.
[http://dx.doi.org/10.1515/CCLM.2009.110] [PMID: 19327124]
[59]
Sharma A, Khan R, Gupta N, et al. Acute phase reactant, Pentraxin 3, as a novel marker for the diagnosis of rheumatoid arthritis. Clin Chim Acta 2018; 480: 65-70.
[http://dx.doi.org/10.1016/j.cca.2018.01.035] [PMID: 29408170]
[60]
Del Rincón I, O’Leary DH, Freeman GL, Escalante A. Acceleration of atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis 2007; 195(2): 354-60.
[http://dx.doi.org/10.1016/j.atherosclerosis.2006.09.027] [PMID: 17097659]
[61]
Nurmohamed MT. Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 2009; 8(8): 663-7.
[http://dx.doi.org/10.1016/j.autrev.2009.02.015] [PMID: 19393192]
[62]
Deyab G, Hokstad I, Whist JE, et al. Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. PLoS One 2017; 12(2): e0169830.
[http://dx.doi.org/10.1371/journal.pone.0169830] [PMID: 28225768]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy